Back to today’s briefing

Story perspectives

Nektar Therapeutics Stock Soars 156% After Eczema Drug Success

6/25/2025

30 5

Summary

Story summary

Nektar Therapeutics' stock skyrocketed by 156% following promising Phase 2b trial results for its eczema treatment, rezpegaldesleukin. Patients experienced a remarkable 53%-61% improvement in symptoms, far surpassing the 31% seen with placebo. With a solid safety record, the drug is also under investigation for severe alopecia areata, with results anticipated in 2025 and 2026.

1 of 1

Story summary

Nektar Therapeutics' stock skyrocketed by 156% following promising Phase 2b trial results for its eczema treatment, rezpegaldesleukin. Patients experienced a remarkable 53%-61% improvement in symptoms, far surpassing the 31% seen with placebo. With a solid safety record, the drug is also under investigation for severe alopecia areata, with results anticipated in 2025 and 2026.